Compare RRBI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRBI | PRME |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 591.3M | 666.1M |
| IPO Year | 2019 | 2022 |
| Metric | RRBI | PRME |
|---|---|---|
| Price | $90.79 | $3.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 51.9K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 28.89 | 18.18 |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $12.72 | $7.06 |
| Revenue Next Year | $4.35 | $47.01 |
| P/E Ratio | $14.50 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $54.05 | $1.11 |
| 52 Week High | $98.85 | $6.94 |
| Indicator | RRBI | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 36.93 |
| Support Level | $89.04 | $3.17 |
| Resistance Level | $92.74 | $3.97 |
| Average True Range (ATR) | 3.45 | 0.24 |
| MACD | -0.43 | -0.06 |
| Stochastic Oscillator | 50.53 | 12.88 |
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.